02/07/2012 07:35:00

Glaxo, Theravance Get Positive Results From LAMA/LABA (UMEC/VI) in COPD

Related content
02 Feb - 
Adaptimmune and GSK Expand Strategic Immunotherapy Coll..

LONDON--GlaxoSmithKline PLC (GSK.LN) and Theravance, Inc. (THRX) Monday announced positive results from four pivotal phase III studies for once-daily LAMA/LABA (UMEC/VI) in COPD

MAIN FACTS:

-The results of four pivotal phase III studies of investigational LAMA/LABA involving over 4,000 patients with chronic obstructive pulmonary disease.

-These four studies include two 24-week efficacy studies that compared the combination LAMA/LABA, its components and placebo and two 24-week active comparator studies that compared the combination with the LAMA tiotropium, a widely prescribed maintenance bronchodilator for COPD.

-LAMA/LABA is a combination of two investigational bronchodilator molecules - GSK573719 or umeclidinium bromide (UMEC), a long-acting muscarinic antagonist and vilanterol, a long-acting beta2 agonist, administered by a new dry powder inhaler.

-UMEC/VI is a once-daily investigational medicine currently under development for the maintenance treatment of COPD.

-Write to Razak Musah Baba at razak.baba@dowjones.com

(END) Dow Jones Newswires

July 02, 2012 02:35 ET (06:35 GMT)

Copyright (c) 2012 Dow Jones & Company, Inc.

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
Ingen indlæg

Regulatory news

Form 8.3 - Premier Farnell Plc

30/08/2016 15:25:07
            FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1..

Man Group PLC : Form 8.3 - Sainsbury (J) plc

30/08/2016 13:01:00
FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE ..

OZ Management LP : Form 8.3 - J Sainsbury Plc

30/08/2016 10:47:44
FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE ..

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
Corning Unveils Corning® Gorilla® Glass SR+, Designed to Overcome the Unique Challenges of Wearable Devices
2
GLOBAL BIOENERGIES: IBN-One awards front-end engineering design to Technip and IPSB for the first plant converting renewable res
3
VWR Announces Schedule of Investor Conferences for September 2016
4
Starbreeze AB : Majority owner Varvtre AB increases its ownership in Starbreeze in off-market transaction
5
Amendment : Half-year Report

Related stock quotes

Glaxosmithkline PLC ORD .. 1,643.71 0.0% Stock price unchanged
GlaxoSmithKline PLC 43.36 0.0% Stock price unchanged

Buy and sell signals

  • Trend
  • Moneymachine

Copyright Euroinvestor A/S 2016   Disclaimer and Terms of Use
Quote information is delivered by Interactive Data.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
31 August 2016 07:02:16
(UTC) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20160826.1 - EUROWEB6 - 2016-08-31 08:02:16 - 2016-08-31 07:02:16 - 1000 - Website: OKAY